Tilt Investment Management Holdings PBC Has $248,000 Stake in McKesson Co. (NYSE:MCK)

Tilt Investment Management Holdings PBC decreased its holdings in McKesson Co. (NYSE:MCK) by 27.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 535 shares of the company’s stock after selling 198 shares during the period. Tilt Investment Management Holdings PBC’s holdings in McKesson were worth $248,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MCK. Norges Bank acquired a new position in shares of McKesson in the 4th quarter valued at about $633,960,000. International Assets Investment Management LLC grew its stake in shares of McKesson by 1,044.5% in the 4th quarter. International Assets Investment Management LLC now owns 821,262 shares of the company’s stock valued at $380,228,000 after buying an additional 749,504 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of McKesson by 16.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock valued at $2,238,953,000 after buying an additional 708,438 shares in the last quarter. Moneta Group Investment Advisors LLC grew its stake in shares of McKesson by 94,078.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 596,151 shares of the company’s stock valued at $223,628,000 after buying an additional 595,518 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of McKesson by 53.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 915,949 shares of the company’s stock valued at $280,399,000 after buying an additional 320,588 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Down 1.4 %

Shares of MCK stock opened at $518.81 on Friday. The stock has a 50 day moving average of $524.44 and a 200-day moving average of $485.71. The firm has a market cap of $68.18 billion, a PE ratio of 23.51, a price-to-earnings-growth ratio of 1.43 and a beta of 0.45. McKesson Co. has a 12 month low of $352.34 and a 12 month high of $543.00.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating analysts’ consensus estimates of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to analyst estimates of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. McKesson’s revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company posted $6.90 earnings per share. As a group, equities analysts predict that McKesson Co. will post 27.59 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 1st were paid a $0.62 dividend. The ex-dividend date was Thursday, February 29th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.48%. McKesson’s payout ratio is 11.24%.

Insider Activity at McKesson

In related news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at $22,789,074.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Leann B. Smith sold 186 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now owns 1,511 shares of the company’s stock, valued at $749,456. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MCK. Citigroup boosted their price target on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Barclays initiated coverage on McKesson in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 price target for the company. SVB Leerink initiated coverage on McKesson in a research report on Monday, February 26th. They set an “outperform” rating and a $600.00 target price for the company. UBS Group upped their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Finally, Mizuho upped their target price on McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.